MDS (Myelodysplastic Syndrome)

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or  via email CSmith@GabrailCancerCenter.com.

***NEW*** A phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell Transfusion (RBC) Transfusion Burden (LTB)

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia sue to IPSS-R very low, low, or intermediate risk Myelodyplastic Syndromes in Subjects with ring Sideroblasts who required red blood cell transfusions The “MEDALIST” Trial

 

Return to Clinical Trials at GCC